About
Kinimmune develops localized immunotherapy treatments for solid tumors, utilizing proprietary peptide-TLR agonists to activate the immune system at tumor sites and enhance therapeutic responses.
Explore Kinimmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.